FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4321059365> ?p ?o ?g. }

• W4321059365 endingPage "815" @default.
• W4321059365 startingPage "812" @default.
• W4321059365 abstract "No AccessJournal of UrologyVesicoureteral Reflux1 Aug 1995Physical and Histological Behavior of a New Injectable Collagen (GAX 65) Implanted into the Submucosal Space of the Mini-Pig Bladder P. Frey and S. Mangold P. FreyP. Frey More articles by this author and S. MangoldS. Mangold More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)67171-4AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail The aim of our study was to analyze the physical and histological behavior of a second generation collagen (GAX 65*) in the mini-pig bladder, comparing it to the commonly used substance for injection (GAX 35*). GAX 65 is a glutaraldehyde cross-linked bovine collagen with a collagen concentration of 65 mg./ml. This much higher collagen concentration could be achieved due to sophisticated manufacturing technology. In 18 mini-pigs 2 to 4, 1 ml. deposits of GAX 65 and 35, respectively, were implanted into the submucosal space of the surgically opened bladder. The animals were sacrificed at months 1, 2, 4 and 6. The elevation (height equals protrusion of the implant into the bladder) and volume of the implants were measured and calculated immediately after injection and at necropsy. Histology was performed. The GAX 65 implants had a lesser decrease of elevation and volume during the 6-month observation period. Histology showed that the invasion of endogenous fibroblasts into the GAX 35 and 65 implants, and the formation of porcine collagen types I and III were almost identical. Clinically GAX 65 has better elevation properties than GAX 35 although statistical analysis did not show any significant difference (p = 0.07 to 0.25). However, preservation of the volume of the GAX 65 implant was significantly superior (p less than or equal to 0.05) compared to that of GAX 35. Therefore, GAX 65 will most probably prove to be an excellent substance for the endoscopic treatment of vesicoureteral reflux and incontinence in children. References 1 : Subureteral collagen injection for the endoscopic treatment of vesicoureteral reflux in children. Followup study of 97 treated ureters and histological analysis of collagen implants. J. Urol., part 21992; 148: 718. Abstract, Google Scholar 2 : Submucosal bladder neck injections of glutaraldehyde cross-linked bovine collagen for treatment of structural incontinence in patients with exstrophy/epispadias complex. Dial. Ped. Urol.1994; 17: 2. Google Scholar 3 : Clinical assessment of Zyplast implant: a year of experience for soft tissue contour correction. J. Amer. Acad. Dermatol.1988; 18: 707. Google Scholar 4 : Injectable collagen in laryngeal rehabilitation. Laryngoscope1984; 94: 513. Google Scholar 5 : Zur quantitativen polarisationsmikroskopischen Darstellung von Kollagen Typ I und Typ III an histologischen Paraffinschnitten. Z. Rechtsmed.1988; 100: 101. Google Scholar 6 : Endoscopic subureteric collagen injection (SCIN): a new alternative treatment of vesicoureteric reflux in children. Experience in 82 refluxing ureters. Ped. Surg. Int.1991; 6: 287. Google Scholar 7 : The long-term histological results following glutaraldehyde cross-linked collagen injection into the suburothelial space of the mini-pig bladder. Ped. Surg. Int.1991; 6: 252. Google Scholar 8 : Histological behavior of glutaraldehyde cross-linked bovine collagen injected into the human bladder for the treatment of vesicoureteral reflux. J. Urol., part 21994; 152: 632. Abstract, Google Scholar Department of Pediatric Surgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.© 1995 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byINOUE K, NAKAMOTO T, USUI A and USUI T (2018) EVALUATION OF ANTIBODY CLASS IN RESPONSE TO ENDOSCOPIC SUBURETERAL COLLAGEN INJECTION IN PATIENTS WITH VESICOURETERAL REFLUXJournal of Urology, VOL. 165, NO. 2, (555-558), Online publication date: 1-Feb-2001.INOUE K, NAKAMOTO T, USUI A and USUI T (2018) ENDOSCOPIC SUBURETERAL GLUTARALDEHYDE CROSS-LINKED COLLAGEN INJECTION FOR THE TREATMENT OF SECONDARY VESICOURETERAL REFLUX: COMPARISON WITH PRIMARY VESICOURETERAL REFLUX IN ADULTSJournal of Urology, VOL. 164, NO. 2, (336-339), Online publication date: 1-Aug-2000.Frey P, Gudinchet F and Jenny P (2018) Gax 65: A New Injectable Cross-Linked Collagen for the Endoscopic Treatment of Vesicoureteral Reflux-A Double-Blind Study Evaluating Its Efficiency in ChildrenJournal of Urology, VOL. 158, NO. 3, (1210-1212), Online publication date: 1-Sep-1997. Volume 154Issue 2August 1995Page: 812-815 Advertisement Copyright & Permissions© 1995 by American Urological Association, Inc.MetricsAuthor Information P. Frey More articles by this author S. Mangold More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W4321059365 created "2023-02-17" @default.
• W4321059365 creator A5005949087 @default.
• W4321059365 creator A5016868143 @default.
• W4321059365 date "1995-08-01" @default.
• W4321059365 modified "2023-10-16" @default.
• W4321059365 title "Physical and Histological Behavior of a New Injectable Collagen (GAX 65) Implanted into the Submucosal Space of the Mini-Pig Bladder" @default.
• W4321059365 cites W2003296654 @default.
• W4321059365 cites W2056251102 @default.
• W4321059365 cites W2170614583 @default.
• W4321059365 cites W2314096552 @default.
• W4321059365 cites W2417624657 @default.
• W4321059365 cites W2429432374 @default.
• W4321059365 cites W2884541341 @default.
• W4321059365 doi "https://doi.org/10.1016/s0022-5347(01)67171-4" @default.
• W4321059365 hasPublicationYear "1995" @default.
• W4321059365 type Work @default.
• W4321059365 citedByCount "11" @default.
• W4321059365 crossrefType "journal-article" @default.
• W4321059365 hasAuthorship W4321059365A5005949087 @default.
• W4321059365 hasAuthorship W4321059365A5016868143 @default.
• W4321059365 hasConcept C105702510 @default.
• W4321059365 hasConcept C126894567 @default.
• W4321059365 hasConcept C141071460 @default.
• W4321059365 hasConcept C142724271 @default.
• W4321059365 hasConcept C2781411149 @default.
• W4321059365 hasConcept C57742111 @default.
• W4321059365 hasConcept C71924100 @default.
• W4321059365 hasConceptScore W4321059365C105702510 @default.
• W4321059365 hasConceptScore W4321059365C126894567 @default.
• W4321059365 hasConceptScore W4321059365C141071460 @default.
• W4321059365 hasConceptScore W4321059365C142724271 @default.
• W4321059365 hasConceptScore W4321059365C2781411149 @default.
• W4321059365 hasConceptScore W4321059365C57742111 @default.
• W4321059365 hasConceptScore W4321059365C71924100 @default.
• W4321059365 hasIssue "2" @default.
• W4321059365 hasLocation W43210593651 @default.
• W4321059365 hasOpenAccess W4321059365 @default.
• W4321059365 hasPrimaryLocation W43210593651 @default.
• W4321059365 hasRelatedWork W1480599264 @default.
• W4321059365 hasRelatedWork W1966846596 @default.
• W4321059365 hasRelatedWork W2042251235 @default.
• W4321059365 hasRelatedWork W2352799530 @default.
• W4321059365 hasRelatedWork W2392413698 @default.
• W4321059365 hasRelatedWork W2398260538 @default.
• W4321059365 hasRelatedWork W2408693058 @default.
• W4321059365 hasRelatedWork W2620996997 @default.
• W4321059365 hasRelatedWork W4309436608 @default.
• W4321059365 hasRelatedWork W2118673085 @default.
• W4321059365 hasVolume "154" @default.
• W4321059365 isParatext "false" @default.
• W4321059365 isRetracted "false" @default.
• W4321059365 workType "article" @default.